期刊
JOURNAL OF PHARMACOLOGICAL SCIENCES
卷 136, 期 4, 页码 212-217出版社
JAPANESE PHARMACOLOGICAL SOC
DOI: 10.1016/j.jphs.2017.12.013
关键词
Curcumin; Demethoxycurcumin; Bisdemethoxycurcumin p300; Cardiomyocyte hypertrophy
资金
- Japan Science and Technology Agency [26460071, 15K21279, 25860052]
- Japan Society for the Promotion of Sciences [LS061]
- Grants-in-Aid for Scientific Research [25860052, 15K21279, 17H06401, 26460071] Funding Source: KAKEN
The natural compound, curcumin (CUR), possesses several pharmacological properties, including p300-specific histone acetyltransferase (HAT) inhibitory activity. In our previous study, we demonstrated that CUR could prevent the development of cardiac hypertrophy by inhibiting p300-HAT activity. Other major curcuminoids isolated from Curcuma longa including demethoxycurcumin (DMC) and bisdemethoxycurcumin (BDMC) are structural analogs of CUR. In present study, we first confirmed the effect of these three curcuminoid analogs on p300-HAT activity and cardiomyocyte hypertrophy. Our results showed that DMC and BDMC inhibited p300-HAT activity and cardiomyocyte hypertrophy to almost the same extent as CUR. As the three compounds have structural differences in methoxy groups at the 3-position of their phenol rings, our results suggest that these methoxy groups are not involved in the inhibitory effects on p300-HAT activity and cardiac hypertrophy. These findings provide useful insights into the structure-activity relationship and biological activity of curcuminoids for p300-HAT activity and cardiomyocyte hypertrophy. (C) 2018 The Authors. Production and hosting by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据